FDA has approved AUVELITY (dextromethorphan HBr and bupropion HCl) for the treatment of agitation associated with dementia due to Alzheimer’s disease. The approval makes AUVELITY the first rapid‑acting oral, non‑antipsychotic therapy for this indication and extends the drug’s commercial reach beyond its existing major depressive disorder indication.
The approval was based on two Phase 3 trials, ADVANCE‑1 and ACCORD‑2, which demonstrated significant improvement in agitation scores and a favorable safety profile. AUVELITY targets N‑methyl‑D‑aspartate (NMDA) and sigma‑1 receptors, and the drug received Breakthrough Therapy designation in 2020 and was reviewed under Priority Review.
Analysts estimate the peak sales for AUVELITY in the Alzheimer’s‑agitation market could exceed $2.1 billion, with TD Cowen projecting a $1 billion market. The drug addresses a population of more than 7 million U.S. patients, with agitation prevalence ranging from 50 % to 76 %. It competes with Rexulti, the only other FDA‑approved treatment for this indication, but offers a non‑antipsychotic mechanism and a potentially better safety profile.
Axsome’s financial context underscores the significance of the new indication. In Q1 2025 the company generated $121.5 million in revenue, of which $96.2 million came from AUVELITY. Q4 2025 revenue rose to $196 million, with AUVELITY sales of $155.1 million. Full‑year 2025 revenue reached $638.5 million, with a net loss of $183.2 million, but the company held $322.9 million in cash. AUVELITY’s major depressive disorder sales exceeded $500 million in 2025, providing a robust commercial infrastructure that can be leveraged for the new indication.
"The approval of our first‑in‑class medication for agitation associated with Alzheimer disease marks an important milestone for the millions of patients living with Alzheimer disease, their families, and their caregivers. We are very pleased to deliver to clinicians and patients a new, effective, FDA‑approved treatment option, with a distinct mechanism of action, for this debilitating and critically underserved condition," said Herriot Tabuteau, MD, CEO of Axsome.
"Auvelity was found to be efficacious for treating agitation in Alzheimer’s disease in two randomized trials and now represents an additional option to address one of the most difficult sequelae of the disease, especially as it progresses. We hope this approval will provide meaningful benefit to patients, their families, and caregivers," said Tracy Beth Hoeg, M.D., Ph.D., Acting Director of the FDA’s Center for Drug Evaluation and Research.
The announcement was well received by investors, reflecting confidence in the new indication and the company’s growth prospects. The approval positions Axsome as a leader in the central nervous system market and sets the stage for accelerated commercial launch and broader payer coverage.
The FDA approval expands AUVELITY’s addressable market, strengthens Axsome’s revenue pipeline, and underscores the company’s commitment to developing innovative therapies for serious brain health conditions. With a solid commercial foundation and a sizable new market opportunity, the approval is a key catalyst for future growth.
The content on EveryTicker is for informational purposes only and should not be construed as financial or investment advice. We are not financial advisors. Consult with a qualified professional before making any investment decisions. Any actions you take based on information from this site are solely at your own risk.